Key result
Diazoxide linked to a 7% incidence of pulmonary hypertension in hyperinsulinaemic hypoglycaemia.
Why the study?
Diazoxide is first-line treatment for hyperinsulinaemic hypoglycaemia but diazoxide-induced pulmonary hypertension can occur, and its incidence and risk factors need characterization.
What is the incidence and what are the risk factors for diazoxide-induced pulmonary hypertension in patients with hyperinsulinaemic hypoglycaemia?
Cohort (n=177)
Yes
What is the incidence and what are the risk factors for diazoxide-induced pulmonary hypertension in patients with hyperinsulinaemic hypoglycaemia?
Diazoxide-induced pulmonary hypertension occurs in 7% of treated patients with hyperinsulinaemic hypoglycaemia, with congenital heart disease and fluid overload identified as significant risk factors.
Answers are grounded in this paper and cite their sources.
May warrant PH monitoring in diazoxide-treated HH; leaves open prospective validation of incidence and risk factors.
OBJECTIVE: Diazoxide is first-line treatment for hyperinsulinaemic hypoglycaemia (HH) but diazoxide-induced pulmonary hypertension (PH) can occur. We aim to characterize the incidence and risk factors of diazoxide-induced PH in a large HH cohort to provide recommendations for anticipating and preventing PH in diazoxide-treated patients with HH. DESIGN AND PATIENTS: Retrospective cohort study involving four UK regional HH centres; review of case notes of HH patients on diazoxide. MEASUREMENTS: The diagnosis of PH was based on clinical and echocardiography evidence. Patient and treatment-related risk factors were analysed for association. RESULTS: Thirteen (6 men) of 177 HH diazoxide-treated patients developed PH, an incidence of 7%. In the PH group, HH was diagnosed at median (range) of 9 (1,180) days, with diazoxide commenced 4 (0,76) days from diagnosis and reaching a maximum dose of 7 (2.5,20) mg/kg/d. The majority (8 of 13 patients) developed PH within 2 weeks of diazoxide. Complete diazoxide withdrawal, but not dose reduction, led to PH resolution at 41 (3,959) days. In three patients, PH continued beyond 12 months. Risk factors for the development of PH included the presence of congenital heart disease (CHD) (P = .008), and total fluid volume exceeding 130 mL/kg/d in the immediate 24 hours preceding diazoxide (P = .019). CONCLUSION: Pulmonary hypertension can occur in 7% of diazoxide-treated HH patients. Risk factors include the presence of congenital heart disease and fluid overload. Recommendations include echocardiography and fluid restriction to 130 mL/kg/d prior to diazoxide treatment and immediate discontinuation of diazoxide if PH develops.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2019) conducted a cohort in Hyperinsulinaemic hypoglycaemia (n=177). Diazoxide was evaluated on Incidence of pulmonary hypertension. Diazoxide treatment in patients with hyperinsulinaemic hypoglycaemia was associated with a 7% incidence of pulmonary hypertension, with congenital heart disease and fluid overload as risk factors.
Synapse has enriched 10 related papers. Consider them for comparative context: